SKB BIO-B (06990) opened more than 5% higher, currently up 5.37% at HKD 483, with a trading volume of HKD 1.5939 million. The company announced that it presented several clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference, being held in Berlin, Germany from October 17 to 21. The results include data on the anti-TROP2 antibody-drug conjugate sac-TMT (佳泰萊®), the anti-HER2 ADC A166 (舒泰萊®), and Claudin18.2 ADC SKB315.